Los Angeles Capital Management
CLDX icon

Los Angeles Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Los Angeles Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.31K Hold
262
– – ﹤0.01% 1997
2025
Q4 		$6.81K Buy
+262
New +$6.9K ﹤0.01% 2212
2025
Q1 		– Sell
-15,421
Closed -$390K – 1103
2024
Q4 		$390K Buy
15,421
+8,683
+129% +$236K ﹤0.01% 872
2024
Q3 		$229K Sell
6,738
-633
-9% -$24.1K ﹤0.01% 1088
2024
Q2 		$273K Buy
7,371
+638
+9% +$24.1K ﹤0.01% 1045
2024
Q1 		$283K Buy
+6,733
New +$276K ﹤0.01% 1022
2023
Q4 		– Sell
-16,082
Closed -$443K – 1144
2023
Q3 		$443K Buy
16,082
+56
+0.3% +$1.75K ﹤0.01% 851
2023
Q2 		$544K Buy
+16,026
New +$540K ﹤0.01% 827
2014
Q2 		– Sell
-2,435
Closed -$646K – 1215
2014
Q1 		$646K Buy
+2,435
New +$932K 0.01% 789

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return